HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Weekly (Nov.3)-Share Price Correction,Valuable Shortcut,Globalization Vs Innovation

CanSino Biologics (6185.HK/688185.CH) 23Q3 - Some Positive Business Progress Worth the Attention

China Healthcare Weekly (Nov.10) - 9th National VBP, Cyclicity of CXO Sector, Asymchem, Hengrui

GSK Inks Eye-Popping $2B-Plus Pact for Hansoh’s ADC - Is The "New Story" About to Begin?

Pre-IPO WuXi XDC - The Beautiful Story and the Truth Behind

Angelalign Technology (6699.HK) - Profit Margin Will Continue to Be Under Pressure

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

Livzon Pharmaceutical Group / Equity Bottom-Up

<ul>
<li>The results of the first VBP of TCM formula granules in China were announced. 200 varieties of TCM formula granules have been included, with an average price reduction of 50.77%.</li>
<li>According to the recently released <em>Statistical Bulletin on the Development of Health Care in 2022</em>, we have listed some key points worth investors' attention.</li>
<li>Livzon’s 23Q3 performance was below expectations, which was more related to external factors such as anti-corruption campaign, VBP. However, Chairman's share buyback proposal indicates possibility of a future reversal.</li>
</ul>


The results of the first VBP of TCM formula granules in China were announced. 200 varieties of TCM formula granules have been included, with an average price reduction of 50.77%.
According to the recently released Statistical Bulletin on the Development of Health Care in 2022, we have listed some key points worth investors' attention.
Livzon’s 23Q3 performance was below expectations, which was more related to external factors such as anti-corruption campaign, VBP. However, Chairman's share buyback proposal indicates possibility of a future reversal.


China Traditional Chinese Medicine (570 HK)

China Resources Sanjiu Medical & Pharma (000999 CH)

Livzon Pharmaceutical Group In (000513 CH)

China Healthcare Weekly (Oct.27) - TCM Formula Granules VBP, Medical Statistics to Watch, Livzon